Anti‐TNF alpha medications and neuropathy

We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the peripheral nervous system Vol. 20; no. 4; pp. 397 - 402
Main Authors: Tsouni, Pinelopi, Bill, Olivier, Truffert, André, Liaudat, Christelle, Ochsner, François, Steck, Andreas J., Kuntzer, Thierry
Format: Journal Article
Language:English
Published: Malden, USA Wiley Periodicals, Inc 01.12.2015
Wiley Subscription Services, Inc
Subjects:
Adalimumab - adverse effects
Adalimumab - therapeutic use
Adult
Aged
anti‐TNF alpha
Autoimmune Diseases - drug therapy
demyelination
Electrodiagnosis
Etanercept - adverse effects
Etanercept - therapeutic use
Female
Humans
inflammation
Infliximab - adverse effects
Infliximab - therapeutic use
Male
Middle Aged
Neural Conduction - physiology
neuropathies
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - diagnosis
Peripheral Nervous System Diseases - physiopathology
Rheumatic Diseases - drug therapy
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
neuropathies
anti-TNF alpha
inflammation
demyelination
ISSN:1085-9489, 1529-8027, 1529-8027
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1085-9489
1529-8027
1529-8027
DOI:10.1111/jns.12147